Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From the LIBERATE Study.

about

Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From the LIBERATE Study.

Item

http://www.wikidata.org/entity/Q45983415

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@en

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@nl

type

Item

label

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@en

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@nl

prefLabel

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@en

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@nl

P1476

Safety and Efficacy of Apremil ...... dings From the LIBERATE Study.

@en

P2093

A Bewley

http://www.w3.org/2001/XMLSchema#string

J Cirulli

http://www.w3.org/2001/XMLSchema#string

J Marcsisin

http://www.w3.org/2001/XMLSchema#string

J Soung

http://www.w3.org/2001/XMLSchema#string

K Reich

http://www.w3.org/2001/XMLSchema#string

L Green

http://www.w3.org/2001/XMLSchema#string

M Gooderham

http://www.w3.org/2001/XMLSchema#string

R Chen

http://www.w3.org/2001/XMLSchema#string

R Petric

http://www.w3.org/2001/XMLSchema#string

V Piguet

http://www.w3.org/2001/XMLSchema#string

P2860

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

P304

397-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.14738

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29220542

http://www.w3.org/2001/XMLSchema#string

P932

5873268

http://www.w3.org/2001/XMLSchema#string